Related Experiment Videos
Adynamic bone disease: pathogenesis, diagnosis and clinical relevance
1Division of Nephrology, Wellesley Central Hospital, University of Toronto, Ontario, Canada.
Current Opinion in Nephrology and Hypertension
|July 1, 1997
Summary
Adynamic bone disease in uremic patients results from complex factors, not a single cause. Research explores receptor downregulation, erythropoietin links, and bone-specific alkaline phosphatase as diagnostic tools.
Area of Science:
- Nephrology
- Endocrinology
- Bone Biology
Background:
- Adynamic bone disease (ABD) is prevalent in uremic patients.
- Its pathogenesis involves multiple complex factors.
- Recent research highlights receptor downregulation and potential links to erythropoietin.
Purpose of the Study:
- To review current understanding of adynamic bone disease pathogenesis in uremia.
- To explore potential diagnostic markers and preventive strategies.
Main Methods:
- Literature review of recent publications on adynamic bone disease.
- Analysis of proposed pathogenetic mechanisms, including receptor downregulation.
- Evaluation of diagnostic markers like bone-specific alkaline phosphatase.
- Discussion of therapeutic interventions such as dialysate calcium concentration.
Main Results:
- Parathyroid hormone/parathyroid hormone-related peptide receptor downregulation on osteoblast-like cells is a key pathogenetic step.
- Erythropoietin use is hypothesized to contribute to ABD development.
- Bone-specific alkaline phosphatase shows potential for differentiating bone turnover rates.
- Lowering dialysate calcium is discussed as a preventive measure.
Conclusions:
- Adynamic bone disease pathogenesis is multifactorial.
- Further research is needed to validate bone-specific alkaline phosphatase as a diagnostic marker.
- Understanding these factors is crucial for improving patient care in uremia.